Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2020 | Highlights from SABCS 2020

Nadia Harbeck • 14 Dec 2020
SABCS 2020
Breast Cancer Anastrozole Cyclophosphamide Docetaxel Epirubicin Exemestane Letrozole Paclitaxel Tamoxifen Citrate Trastuzumab deruxtecan
ADAPT RxPONDER

Nadia Harbeck, MD, PhD, LMU Munich, Munich, Germany, discussing ongoing breast cancer clinical trials, including the ADAPT trial (NCT01779206), RxPONDER trial (NCT01272037), and DESTINY-Breast01 (NCT03248492) which suggest high clinical response rates and could reduce the need for chemotherapy in 60% of early breast cancer patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Nadia Harbeck

4:02
Assessment of short preoperative endocrine therapy in the ADAPT and ADAPTcycle trials
Nadia Harbeck • 20 Sep 2022
4:11
The latest in neo-adjuvant therapy for luminal breast cancer
Nadia Harbeck • 20 Sep 2022
2:35
Treatment options for high risk early breast cancer
Nadia Harbeck • 20 Sep 2022
0:55
The clinical impact of gene expression assays on early luminal breast cancer
Nadia Harbeck • 4 May 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals